Patent SG-11201908788Y-A (SG)
Title: Combinations of chk1- and wee1 - inhibitors
Inventor: VO ALEX
IPC: A61K31/519
Filed: 2018-03-30
Abstract: 28 Study Day u mor Vo lu me ( m m 2500- 2000- 1500- 1000- 500- 1-1 Cr) 00 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT onion °nolo 0l 001 oimIE (10) International Publication Number WO 2018/183891 Al (51) International Patent Classification: A61K 9/00 (2006.01) A61P 35/00 A61K 45/06 (2006.01) A61P 35/02 A61K 31/497 (2006.01) A61P 35/04 A61K 31/519 (2006.01) (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/480,101 31 March 2017 (31.03.2017) US (71) Applicant: CASCADIAN THERAPEUTICS [US/US]; 2601 4th Ave., Suite 500, Seattle, Washington 98121 (US). (72) Inventors: VO, Alex; c/o Cascadian Therapeutics, 2601 4th Ave., Suite 500, Seattle, Washington 98121 (US). KLUCHER, Kevin; c/o Cascadian Therapeutics, 2601 4th Ave., Suite 500, Seattle, Washington 98121 (US). PE- TERSON, Scott; c/o Cascadian Therapeutics, 2601 4th Ave., Suite 500, Seattle, Washington 98121 (US). (74) Agent: ZYLSTRA, Eric J. et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (2006.01) (2006.01) (2006.01) (21) International Application Number: PCT/US2018/025464 (54) Title: COMBINATIONS OF CHK1- AND WEE1 - INHIBITORS FIG. 14A Jeko-1 Tumor Growth Vehicle ' 4-- Compound 1 7.5 mg/kg QD AZD-1775 15 mg kg QD -V- Compound 1 7.5 mg/kg + AZD-1775 15 mg/kg QD 3-on/4-off X 3 cycles 1-1 (57) : In one aspect, the present invention provides a method for preventing or treating cancer in a subject. In some embod- • iments, the method comprises administering a therapeutically effective amount of the Chkl inhibitor Compound 1. In other embodi- ments, the method further comprises administering a therapeutically effective amount of a Weel inhibitor. Pharmaceutical compositions 0 and kits are also provided herein.